| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
55,360,000 |
| Market
Cap: |
240.82(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.47 - $5.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 17.7 |
| Insider 6 Months : 19 |
| Insider 3/6 Months : 36.2 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rezolute is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases related to chronic glucose imbalance. Co.'s primary clinical asset, RZ358, is a potential treatment for congenital hyperinsulinism, a pediatric genetic disorder characterized by excessive production of insulin by the pancreas. Co.'s second clinical asset, RZ402, is an oral plasma kallikrein inhibitor being developed as a potential therapy for the chronic treatment of diabetic macular edema.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,258,652 |
1,300,954 |
1,324,213 |
2,831,482 |
| Total Buy Value |
$4,114,085 |
$4,253,784 |
$4,358,101 |
$9,930,062 |
| Total People Bought |
5 |
6 |
6 |
6 |
| Total Buy Transactions |
6 |
10 |
13 |
36 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2025-06-25 |
4 |
B |
$4.38 |
$10,939 |
D/D |
2,500 |
15,500 |
0.01 |
-0% |
|
| Evans Daron |
CFO |
• • – |
2025-06-24 |
4 |
B |
$4.05 |
$20,250 |
D/D |
5,000 |
268,900 |
0.01 |
2% |
|
| Kreher Nerissa |
|
• • – |
2025-06-13 |
4 |
B |
$3.25 |
$9,997 |
D/D |
3,076 |
37,576 |
0.01 |
3% |
|
| Kim Young-Jin |
|
• • – |
2025-06-13 |
4 |
B |
$3.25 |
$3,999,999 |
I/I |
1,230,769 |
8,423,386 |
0.01 |
3% |
|
| Labrucherie Gil M |
|
• • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
34,500 |
|
- |
|
| Hogenhuis Wladimir |
|
• • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
93,025 |
|
- |
|
| Kreher Nerissa |
|
• • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
34,500 |
|
- |
|
| Evans Daron |
CFO |
• • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
263,900 |
|
- |
|
| Fauchet Philippe |
|
• • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
34,500 |
|
- |
|
| Elam Nevan C |
CEO |
• • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
68,000 |
292,119 |
|
- |
|
| Kim Young-Jin |
|
• • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
149,950 |
|
- |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
157,352 |
|
- |
|
| Hogenhuis Wladimir |
|
• • – |
2025-03-31 |
4 |
B |
$2.92 |
$19,733 |
D/D |
6,758 |
84,025 |
0.01 |
49% |
|
| Elam Nevan C |
CEO |
• • – |
2025-03-27 |
4 |
B |
$2.85 |
$34,999 |
D/D |
12,302 |
224,119 |
0.01 |
48% |
|
| Evans Daron |
CFO |
• • – |
2025-03-26 |
4 |
B |
$2.88 |
$28,800 |
I/I |
10,000 |
23,000 |
0.01 |
58% |
|
| Evans Daron |
CFO |
• • – |
2025-03-26 |
4 |
B |
$2.89 |
$28,900 |
D/D |
10,000 |
237,900 |
0.01 |
58% |
|
| Hogenhuis Wladimir |
|
• • – |
2025-02-18 |
4 |
B |
$4.70 |
$47,000 |
D/D |
10,000 |
77,267 |
0.01 |
-10% |
|
| Hogenhuis Wladimir |
|
• • – |
2025-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
25,500 |
67,267 |
|
- |
|
| Labrucherie Gil M |
|
• • – |
2025-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
25,500 |
25,500 |
|
- |
|
| Kim Young-Jin |
|
• • – |
2025-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
25,500 |
140,950 |
|
- |
|
| Fauchet Philippe |
|
• • – |
2025-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
25,500 |
25,500 |
|
- |
|
| Kreher Nerissa |
|
• • – |
2025-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
25,500 |
25,500 |
|
- |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2025-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
77,000 |
131,352 |
|
- |
|
| Evans Daron |
CFO |
• • – |
2025-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
77,000 |
227,900 |
|
- |
|
| Elam Nevan C |
CEO |
• • – |
2025-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
204,000 |
211,817 |
|
- |
|
148 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (0.93%) 
